Comprehensive Analysis Identifies FCER1A as a Potential Link Between Immune Dysregulation and Therapeutic Responses in Systemic Lupus Erythematosus and Gastric Cancer

INTRODUCTION: Systemic lupus erythematosus (SLE) patients exhibit an elevated risk of gastric cancer (GC), yet the molecular mechanisms underlying this comorbidity remain poorly understood. This study presents a novel integrative bioinformatics framework to identify shared molecular signatures between SLE and GC and to assess their prognostic implications. METHODS: This study retrieved microarray data from the GSE50772 and GSE81622 datasets in the GEO database and RNA-seq data from the GC cohort in TCGA. Following screening, this study identified differentially expressed genes (DEGs) and further characterized them based on their differential expression. This study identified the common DEGs (co-DEGs) and performed GO and KEGG pathway analyses to identify relevant pathways, immune infiltration, and gene diagnostic value in the context of SLE and GC. RESULTS: By analyzing three independent datasets (GSE50772, GSE81622, and TCGA_STAD), this study identified 12 co-DEGs, among which FCER1A was validated as an independent prognostic factor for GC through multivariate Cox regression (HR = 1.184, P = 0.026). In addition, FCER1A expression showed significant positive correlations with infiltration of multiple immune cell types, including macrophages (P = 3.38e-27, r = 0.52, 95% CI: 0.44-0.59), CD4+ T cells (P = 7.32e-18, r = 0.43, 95% CI: 0.34-0.51), and neutrophils (P = 5.82e-12, r = 0.35, 95% CI: 0.25-0.43), suggesting its role in shaping the tumor immune microenvironment. Kaplan-Meier analysis confirmed that high FCER1A expression predicted poorer overall survival (P = 0.036) and first progression (P = 0.029). DISCUSSION: In this study, FCER1A was identified as the key gene affected by the combination of SLE and GC. CONCLUSION: This study is the first to systematically link FCER1A-mediated immune infiltration to prognosis in SLE-associated GC, offering a potential biomarker and therapeutic target for this understudied comorbidity.

Authors

Institutions

Publication Details

Journal
Current Medicinal Chemistry
Published
2026-11-12
DOI
https://doi.org/10.2174/0109298673496736261021055415
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comprehensive Analysis Identifies FCER1A as a Potential Link Between Immune Dysregulation and Therapeutic Responses in Systemic Lupus Erythematosus and Gastric Cancer

Tong Liang, Yaqiong Cui, Hongmei Song
Current Medicinal Chemistry
Gastric Cancer Management and Outcomes
article

Comprehensive Analysis Identifies FCER1A as a Potential Link Between Immune Dysregulation and Therapeutic Responses in Systemic Lupus Erythematosus and Gastric Cancer

Tong Liang, Yaqiong Cui, Hongmei Song
article en

Abstract

INTRODUCTION: Systemic lupus erythematosus (SLE) patients exhibit an elevated risk of gastric cancer (GC), yet the molecular mechanisms underlying this comorbidity remain poorly understood. This study presents a novel integrative bioinformatics framework to identify shared molecular signatures between SLE and GC and to assess their prognostic implications. METHODS: This study retrieved microarray data from the GSE50772 and GSE81622 datasets in the GEO database and RNA-seq data from the GC cohort in TCGA. Following screening, this study identified differentially expressed genes (DEGs) and further characterized them based on their differential expression. This study identified the common DEGs (co-DEGs) and performed GO and KEGG pathway analyses to identify relevant pathways, immune infiltration, and gene diagnostic value in the context of SLE and GC. RESULTS: By analyzing three independent datasets (GSE50772, GSE81622, and TCGA_STAD), this study identified 12 co-DEGs, among which FCER1A was validated as an independent prognostic factor for GC through multivariate Cox regression (HR = 1.184, P = 0.026). In addition, FCER1A expression showed significant positive correlations with infiltration of multiple immune cell types, including macrophages (P = 3.38e-27, r = 0.52, 95% CI: 0.44-0.59), CD4+ T cells (P = 7.32e-18, r = 0.43, 95% CI: 0.34-0.51), and neutrophils (P = 5.82e-12, r = 0.35, 95% CI: 0.25-0.43), suggesting its role in shaping the tumor immune microenvironment. Kaplan-Meier analysis confirmed that high FCER1A expression predicted poorer overall survival (P = 0.036) and first progression (P = 0.029). DISCUSSION: In this study, FCER1A was identified as the key gene affected by the combination of SLE and GC. CONCLUSION: This study is the first to systematically link FCER1A-mediated immune infiltration to prognosis in SLE-associated GC, offering a potential biomarker and therapeutic target for this understudied comorbidity.

Current Medicinal ChemistryVol. 33
Gansu University of Traditional Chinese Medicine (CN), Gansu Provincial Hospital (CN)
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon